Human Genome Epidemiology Literature Finder
Pharmacogenomics
Records 1 - 30 (of 559 Records) |
Query Trace: Erlotinib[original query] |
---|
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs. Thoracic cancer 2023 9 . Huang-Chih Chang, Chin-Chou Wang, Chia-Cheng Tseng, Kuo-Tung Huang, Yu-Mu Chen, Yu-Ping Chang, Chien-Hao Lai, Wen-Feng Fang, Meng-Chih Lin, Hung-Yi Chua |
Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence. Thoracic cancer 2023 9 . Huang-Chih Chang, Kuo-Tung Huang, Chia-Cheng Tseng, Yu-Mu Chen, Chien-Hao Lai, Yu-Ping Chang, Yung-Che Chen, Hung-Yi Chuang, Chin-Chou Wa |
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study). Translational lung cancer research 2023 9 12 (8): 1702-1716. Kazuto Nishio, Kazuko Sakai, Makoto Nishio, Takashi Seto, Carla Visseren-Grul, Michelle Carlsen, Tomoko Matsui, Sotaro Enatsu, Kazuhiko Nakaga |
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials. European journal of medical research 2023 8 28 (1): 302. Ruijian Li, Weiyi Li, Fang Zhang, Shanshan |
Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. ESMO open 2023 7 8 (4): 101594. K Tamura, T Yoshida, K Masuda, Y Matsumoto, Y Shinno, Y Okuma, Y Goto, H Horinouchi, N Yamamoto, Y O |
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFRnon-small-cell lung cancer. Translational lung cancer research 2023 7 12 (6): 1167-1184. Makoto Nishio, Shinji Atagi, Koichi Goto, Yukio Hosomi, Takashi Seto, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshige Yoshioka, Naoyuki Nogami, Makoto Maemondo, Seisuke Nagase, Isamu Okamoto, Noboru Yamamoto, Yuriko Igawa, Kosei Tajima, Masahiro Fukuoka, Nobuyuki Yamamoto, Kazuto Nish |
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO open 2023 6 8 (4): 101580. E B Garon, M Reck, K Nishio, J V Heymach, M Nishio, S Novello, L Paz-Ares, S Popat, S Ponce Aix, H Graham, B D Butts, C Visseren-Grul, K Nakagawa, |
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 . Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C Bulusu, Aleksandra Markovets, J Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J Hartmaier, Juliann Chmielecki, Vassiliki A Papadimitrakopoulou, Suresh S Ramaling |
Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant NSCLC. Cancer research and treatment 2023 6 . Beung-Chul Ahn, Charny Park, Moon Soo Kim, Jong Mog Lee, Jin Ho Choi, Hyae Young Kim, Geon Kook Lee, Namhee Yu, Youngjoo Lee, Ji-Youn H |
Colonic mucosal diffuse congestion associated with Osimertinib. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 6 10781552231184182. Xiao-Jun Ren, Ming-Hong Lei, Ying-Xia Cheng, Yun L |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. Targeted oncology 2023 6 . Chao-Hua Chiu, Meng-Chih Lin, Yu-Feng Wei, Gee-Chen Chang, Wu-Chou Su, Te-Chun Hsia, Jian Su, Anne Kuei-Fang Wang, Min-Hua Jen, Tarun Puri, Jin-Yuan Sh |
Retrospective Analysis of the Incidence of Drug-Induced Interstitial Lung Disease by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Survival in Patients Aged 75 Years or Older with Lung Cancer. JMA journal 2023 5 6 (2): 182-187. Masayuki Ishibashi, Yoshiko Nakagawa, Tetsuo Shimizu, Yasuhiro Gon, Hiroshi Yamamo |
The Glasgow prognostic score predicts survival in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations who are treated with EGFR tyrosine kinase inhibitors. Oncology 2023 5 . Yuki Akazawa, Satoshi Igawa, Kaori Yamada, Hiroki Yamamoto, Yuri Yagami, Nobuki Kaizuka, Hiroya Manaka, Masashi Kasajima, Yoshiro Nakahara, Takashi Sato, Hisashi Mitsufuji, Masanori Yokoba, Masaru Kubota, Jiichiro Sasaki, Katsuhiko Nao |
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. Clinical lung cancer 2023 4 . Makoto Nishio, Luis Paz-Ares, Martin Reck, Kazuhiko Nakagawa, Edward B Garon, Sanjay Popat, Matteo Ceccarelli, Hillary T Graham, Carla Visseren-Grul, Silvia Novel |
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. BMC cancer 2023 3 23 (1): 234. Huang Chun-Ta, Lin Chih-An, Su Te-Jen, Yang Ching-Yao, Tsai Tzu-Hsiu, Hsu Chia-Lin, Liao Wei-Yu, Chen Kuan-Yu, Ho Chao-Chi, Yu Chong-J |
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study. The Lancet regional health. Europe 2023 2 27 100592. Gijtenbeek Rolof G P, Damhuis Ronald A M, van der Wekken Anthonie J, Hendriks Lizza E L, Groen Harry J M, van Geffen Wouter |
A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer. Frontiers in oncology 2023 2 13 1095313. Han Shuai, Jiang Dongjie, Zhang Feng, Li Kun, Jiao Kun, Hu Jingyun, Song Haihan, Ma Qin-Yun, Wang Ji |
Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data. Anticancer research 2023 12 44 (1): 257-265. Sarah Sharman Moser, Lior Apter, Josie Solomon, Gabriel Chodick, Miriana Wollner, Nava Siegelmann-Danie |
Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Japanese journal of clinical oncology 2023 11 . Kiyoaki Uryu, Yoshinori Imamura, Rai Shimoyama, Takahiro Mase, Yoshiaki Fujimura, Maki Hayashi, Megu Ohtaki, Keiko Otani, Makoto Hibino, Shigeto Horiuchi, Tomoya Fukui, Ryuta Fukai, Yusuke Chihara, Akihiko Iwase, Noriko Yamada, Yukihiro Tamura, Hiromasa Harada, Nobuaki Shinozaki, Asuka Tsuya, Masahiro Fukuoka, Hironobu Mina |
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC. Scientific reports 2023 11 13 (1): 20323. Jia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, Chi-Hsien Huang, Tzu-Hsuan Chiu, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Ya |
Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma. Medicine 2023 11 102 (45): e35938. Jianzhong Ye, Wen Tian, Bigeng Zheng, Tao Ze |
Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases. Contemporary oncology (Poznan, Poland) 2023 10 27 (2): 71-79. Do Mai Linh, Tran Huy Thinh, Nguyen-Van Hieu, Nguyen Minh D |
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors. Frontiers in oncology 2023 10 13 1249106. Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Ya |
Identification of a cuproptosis-related lncRNA prognostic signature in lung adenocarcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023 1 . Chen Ran, Luo Haichao, Chen Qitian, Wang Changyi |
Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 2023 1 55 e12409. Machado-Rugolo J, Baldavira C M, Prieto T G, Olivieri E H R, Fabro A T, Rainho C A, Castelli E C, Ribolla P E M, Ab'Saber A M, Takagaki T, Nagai M A, Capelozzi V |
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease. JTO clinical and research reports 2024 4 5 (4): 100648. Molly S C Li, Kirsty W C Lee, Kevin K S Mok, Herbert H F Loong, K C Lam, Florence S T Mok, Landon L Chan, Y M Lau, K P Chan, Joyce T Y Ng, Wesley K Y Wong, Benjamin H W Lam, Allen C C Chen, Matthew M P Lee, Olivia H Chen, Tony S K M |
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors. The journal of pathology. Clinical research 2024 1 10 (2): e354. Michael Menzel, Martina Kirchner, Klaus Kluck, Markus Ball, Susanne Beck, Michael Allgäuer, Christin Assmann, Johannes Schnorbach, Anna-Lena Volckmar, Timothy Kwang Yong Tay, Hannah Goldschmid, Daniel Sw Tan, Michael Thomas, Daniel Kazdal, Jan Budczies, Albrecht Stenzinger, Petros Christopoul |
Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis. Frontiers in pharmacology 2024 1 14 1238579. Haosheng Zheng, Xianyu Qin, Yuzhen Zheng, Xingping Yang, Jian Tan, Weijie Cai, Shiyun He, Hongying Li |
Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 1 . Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiaoxu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xueding Wang, Li Zha |
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study. BMC cancer 2024 1 24 (1): 70. Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo She |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: